

**Drug Discovery and Development Solutions Limited**  
**Balance Sheet as at 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

	Notes	As at 31 March 2023	As at 31 March 2022
<b>ASSETS</b>			
<b>Non-current assets</b>			
Financial assets			
Investments	3	29,75,000	55,22,001
Income tax asset (net)		8,950	8,950
<b>Total non-current assets</b>		<b>29,83,950</b>	<b>55,30,951</b>
<b>Current assets</b>			
Financial assets			
Cash and cash equivalents	4	2,76,822	2,37,743
Other financial assets	5	5,21,20,842	3,80,26,382
Other current assets	6	6,153	5,604
<b>Total current assets</b>		<b>5,24,03,817</b>	<b>3,82,69,729</b>
<b>Total assets</b>		<b>5,53,87,767</b>	<b>4,38,00,680</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	7	46,50,001	46,50,001
Other equity		2,42,43,413	1,67,11,939
<b>Total equity</b>		<b>2,88,93,414</b>	<b>2,13,61,940</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Financial liabilities			
Short term borrowings	8	2,63,20,000	2,22,40,000
Trade payables	9	16,912	4,512
Other financial liabilities	10	37,208	1,91,114
Other current liabilities	11	1,20,086	-
Current tax liabilities		147	3,114
<b>Total current liabilities</b>		<b>2,64,94,353</b>	<b>2,24,38,740</b>
<b>Total liabilities</b>		<b>2,64,94,353</b>	<b>2,24,38,740</b>
<b>Total equity and liabilities</b>		<b>5,53,87,767</b>	<b>4,38,00,680</b>

**Benny Thomas**  
**Vice President & CFO**  
Place: Bangalore  
Date: 25-05-2023

**Drug Discovery and Development Solutions Limited**  
**Statement of Profit and Loss for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

<b>Particulars</b>	<b>Notes</b>	<b>For the year ended 31-Mar-23</b>	<b>For the year ended 31-Mar-22</b>
Revenue from operations	12	-	4,69,000
Other income	13	80,95,022	6,06,773
<b>Total income</b>		<b>80,95,022</b>	<b>10,75,773</b>
<b>Expenses</b>			
Employee benefits expense	14	-	4,26,152
Finance costs	15	8,17,570	5,53,967
Other expenses	16	52,277	53,741
<b>Total expenses</b>		<b>8,69,847</b>	<b>10,33,860</b>
<b>Profit before tax</b>		<b>72,25,175</b>	<b>41,913</b>
Tax expense			
- Current tax		1,182	4,363
<b>Total tax expense</b>		<b>1,182</b>	<b>4,363</b>
<b>Profit after tax for the year</b>		<b>72,23,993</b>	<b>37,550</b>
<b>Other comprehensive income</b>			
<i>Items that will not be reclassified to profit or loss</i>			
Exchange differences on translation of foreign operations		-	-
Equity Instrument through Other comprehensive income		-	-
Other comprehensive income for the year, net of tax		-	-
<b>Total comprehensive income for the year</b>		<b>72,23,993</b>	<b>37,550</b>

**Benny Thomas**  
**Vice President & CFO**  
Place: Bangalore  
Date: 25-05-2023

**Drug Discovery and Development Solutions Limited**  
**Statement of Cash Flows for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

<b>Particulars</b>	<b>For the year ended 31 March 2023</b>	<b>For the year 31 March 2022</b>
<b>A. Cash flow from operating activities</b>		
<b>Profit before tax</b>	72,25,175	41,913
Adjustments :		
Finance costs	8,17,570	5,53,967
Profit on sale of investment	(71,54,873)	-
Interest Income	(9,40,149)	(6,06,773)
Other non operating income	-	-
<b>Operating cash flow before working capital changes</b>	<b>(52,277)</b>	<b>(10,893)</b>
Increase in other current assets, loan and advances	(1,40,95,009)	(2,21,62,919)
Decrease in Trade Receivable	-	3,85,000
Increase/(decrease) in trade payables and current liabilities	1,32,486	(3,78,697)
<b>Cash used in operations</b>	<b>(1,40,14,800)</b>	<b>(2,21,67,509)</b>
Income tax paid	(4,148)	(10,199)
<b>Net cash used in operating activities</b>	<b>(1,40,18,948)</b>	<b>(2,21,77,708)</b>
<b>B. Cash flow from investing activities</b>		
Purchase of investments	-	-
Sale of investment	97,01,874	16,69,500
Loan received back from subsidiaries	-	10,00,000
Interest Received	9,40,149	6,06,773
<b>Net cash used in investing activities</b>	<b>1,06,42,023</b>	<b>32,76,273</b>
<b>C. Cash flow arising from financing activities</b>		
Net proceeds from short term borrowings	40,80,000	1,96,00,000
Finance costs paid	(9,71,476)	(5,53,967)
Change in retain earning on account of amalgamation	3,07,480	-
<b>Net cash used in financing activities</b>	<b>34,16,004</b>	<b>1,90,46,033</b>
<b>Net Increase in cash and cash equivalents (A+B+C+D)</b>	<b>39,079</b>	<b>1,44,598</b>
Add: cash and cash equivalents at the beginning of year	2,37,743	93,145
<b>Cash and cash equivalents at the end of the year</b>	<b>2,76,822</b>	<b>2,37,743</b>

**Benny Thomas**  
**Vice President & CFO**  
Place: Bangalore  
Date: 25-05-2023

**Drug Discovery and Development Solutions Limited**  
**Statement of changes in Equity for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

<b>a) Equity share capital</b>	<b>Note</b>	<b>No. of shares</b>	<b>Amount</b>
<b>Balance as at 1 April 2021</b>	7	46,50,001	<b>46,50,001</b>
Changes in equity share capital during the year		-	-
<b>Balance as at 31 March 2022</b>	7	46,50,001	<b>46,50,001</b>
Changes in equity share capital during the year		-	-
<b>Balance as at 31 March 2023</b>	7	46,50,001	<b>46,50,001</b>

**b) Other Equity**

	<b>Reserves and surplus</b>				<b>Total</b>
	<b>Retained earnings</b>	<b>Capital reserve</b>	<b>Equity Instrument through comprehensive income</b>	<b>Other comprehensive income</b>	
<b>Balance as at 1 April 2021</b>	<b>49,68,523</b>	<b>31,19,013</b>	<b>1,78,708</b>	<b>3,34,430</b>	<b>84,21,966</b>
Profit for the year	37,550	-	-	-	37,550
Increase in capital reserve	-	82,52,423	6,39,754	-	82,52,423
Exchange differences on translation of foreign operations	-	-	-	-	-
Reclassification	(98,26,326)	98,26,326	7,19,630	-	-
<b>Balance as at 31 March 2022</b>	<b>(48,20,253)</b>	<b>2,11,97,762</b>	<b>15,38,092</b>	<b>3,34,430</b>	<b>1,67,11,939</b>
<b>Balance as at 1 April 2022</b>	<b>(48,20,253)</b>	<b>2,11,97,762</b>	<b>15,38,092</b>	<b>3,34,430</b>	<b>1,67,11,939</b>
Profit for the year	72,23,993	-	-	-	72,23,993
Addition/(Deletion) on account of amalgamation of JDDPL	(9,15,016)	12,22,497	1,00,484	-	3,07,481
Exchange differences on translation of foreign operations	-	-	-	-	-
Reclassification	85,86,854	(82,52,424)	(6,78,317)	(3,34,430)	-
<b>Balance as at 31 March 2023</b>	<b>1,00,75,578</b>	<b>1,41,67,835</b>	<b>9,60,259</b>	<b>-</b>	<b>2,42,43,413</b>

**Benny Thomas**  
**Vice President & CFO**  
Place: Bangalore  
Date: 25-05-2023

**Note 1: Corporate information**

Drug Discovery and Development Solutions Limited. ("the Company") was incorporated on August 6, 2013 in the Singapore. The Company is a wholly owned subsidiary of Jubilant Pharmova Limited, a company incorporated in India. The principal activities of the Company are those of investment holding.

**Note 2. Significant accounting policies**

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

**(a) Basis of preparation**

**(i) Statement of compliance**

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

**(ii) Historical cost convention**

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

**(b) Functional and presentation currency**

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD.

**(c) Current versus non-current classification**

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

**Drug Discovery and Development Solutions Limited**  
**Notes to the financial statements for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

	As at 31 March 2023	As at 31 March 2022
<b>Note 3. Non-current investments</b>		
<b>I. Investment in subsidiaries</b>		
Jubilant Innovation (USA) Inc 2,975 (31 March 2022: 2,975 equity shares with no par value)	29,75,000	29,75,000
Jubilant Drug Dev Pte Ltd Nil (31 March 2022: 2,547,001 equity shares with no par value)	-	25,47,001
<b>Total Non-Current Investments</b>	<b>29,75,000</b>	<b>55,22,001</b>
<b>Note 4. Cash and cash equivalent</b>		
<b>Balances with banks:</b>		
- On current accounts	2,76,822	2,37,743
	<b>2,76,822</b>	<b>2,37,743</b>
<b>Note 5. Other financial assets</b>		
Advance and interest recoverable-related party	4,300	4,862
Convertible promissory notes to Jubilant Therapeutics Inc	5,21,16,542	3,80,21,520
Interest Receivable	-	-
	<b>5,21,20,842</b>	<b>3,80,26,382</b>
<b>Note 6. Other current assets</b>		
Prepaid expenses	6,153	5,604
	<b>6,153</b>	<b>5,604</b>

**Drug Discovery and Development Solutions Limited**  
**Notes to the financial statements for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

**Note 7: Equity share capital**

	<b>As at 31 March 2023</b>	<b>As at 31 March 2022</b>
<b>Issued, subscribed and paid up share capital</b>		
4,650,001 (31 March 2022: 4,650,001 Equity shares with no par value)	46,50,001	46,50,001
	<b>46,50,001</b>	<b>46,50,001</b>

**1). Movement in Equity share capital**

	<b>Note</b>	<b>No. of shares</b>	<b>Amount</b>
<b>Balance as at 1 April 2021</b>	7	<b>46,50,001</b>	<b>46,50,001</b>
Changes in equity share capital during the year		-	-
<b>Balance as at 31 March 2022</b>	7	<b>46,50,001</b>	<b>46,50,001</b>
Changes in equity share capital during the year		-	-
<b>Balance as at 31 March 2023</b>	7	<b>46,50,001</b>	<b>46,50,001</b>

2) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

3) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

4) The details of shareholders holding more than 5% shares in the company: -

	<b>As at 31 March 2023</b>		<b>As at 31 March 2022</b>	
<b>Name of the Shareholder</b>	<b>No. of shares</b>	<b>% holding in the class</b>	<b>No. of shares</b>	<b>% holding in the class</b>
Jubilant Pharmova Limited	46,50,001	100%	46,50,001	100%

5) The reconciliation of the numebr of shares outstanding as at beginning and at end of the reporting period

	<b>As at 31 March 2023</b>	<b>As at 31 March 2022</b>
	<b>No. of shares</b>	<b>No. of shares</b>
Numbers of shares at the beginning	46,50,001	46,50,001
Add: Shares issued during the year	-	-
Number of shares at the end	<b>46,50,001</b>	<b>46,50,001</b>

**Drug Discovery and Development Solutions Limited**  
**Notes to the financial statements for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

	As at 31 March 2023	As at 31 March 2022
<b>Note 8. Short term borrowings</b>		
Loans from related parties	2,63,20,000	2,22,40,000
	<b>2,63,20,000</b>	<b>2,22,40,000</b>
<b>Note 9. Trade payables</b>		
Trade payables-others	16,912	4,216
Trade payables-Related parties	-	296
	<b>16,912</b>	<b>4,512</b>
<b>Note 10. Other financial liabilities</b>		
Interest payable - related parties	37,208	1,91,114
	<b>37,208</b>	<b>1,91,114</b>
<b>Note 11. Other current liabilities</b>		
Statutory Dues	1,20,086	-
	<b>1,20,086</b>	<b>-</b>

**Drug Discovery and Development Solutions Limited**  
**Notes to the financial statements for the year ended 31 March 2023**  
*(All amounts are in USD, unless stated otherwise)*

	For the year ended As at 31 March 2023	For the year ended 31 March 2022
<b>Note 12 . Revenue from Operations</b>		
Other operating revenue	-	4,69,000
<b>Revenue from operations</b>	<b>-</b>	<b>4,69,000</b>
<b>Note 13. Other income</b>		
Interest income	9,40,149	6,06,773
Net gain on sale of current investments	71,54,873	-
Other non operating income	-	-
	<b>80,95,022</b>	<b>6,06,773</b>
<b>Note 14. Employee Benefits Expenses</b>		
Salaries, wages, bonus, gratuity & allowances	-	3,41,754
Contribution to provident & superannuation fund	-	73,710
Staff welfare expenses	-	10,688
	<b>-</b>	<b>4,26,152</b>
<b>Note 15. Finance cost</b>		
Interest expense	8,17,570	5,53,967
	<b>8,17,570</b>	<b>5,53,967</b>
<b>Note 16. Other expenses</b>		
Auditor's remuneration	7,500	3,650
Legal, professional and consultancy charges	27,994	46,899
Bank charges	2,307	4,171
Rates & Taxes	5,093	8,455
Foreign Exchange Gain	-	(9,434)
Provision/write off Bad Debts / Irrecoverable advances	9,383	-
	<b>52,277</b>	<b>53,741</b>